Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex

Abstract. Viral vector-mediated expression of genes (e.g., coding for opsins and designer receptors) has grown increasingly popular. Cell-type specific expression is achieved by altering viral vector tropism through crosspackaging or by cell-specific promoters driving gene expression. Detailed information about transduction properties of most recombinant adeno-associated viral vector (rAAV) serotypes in macaque cortex is gradually becoming available. Here, we compare transduction efficiencies and expression patterns of reporter genes in two macaque neocortical areas employing different rAAV serotypes and promoters. A short version of the calmodulin-kinase-II (CaMKIIα0.4) promoter resulted in reporter gene expression in cortical neurons for all tested rAAVs, albeit with different efficiencies for spread: rAAV2/5>>rAAV2/7>rAAV2/8>rAAV2/9>>rAAV2/1 and proportion of transduced cells: rAAV2/1>rAAV2/5>rAAV2/7=rAAV2/9>rAAV2/8. In contrast to rodent studies, the cytomegalovirus (CMV) promoter appeared least efficient in macaque cortex. The human synapsin-1 promoter preceded by the CMV enhancer (enhSyn1) produced homogeneous reporter gene expression across all layers, while two variants of the CaMKIIα promoter resulted in different laminar transduction patterns and cell specificities. Finally, differences in expression patterns were observed when the same viral vector was injected in two neocortical areas. Our results corroborate previous findings that reporter-gene expression patterns and efficiency of rAAV transduction depend on serotype, promoter, cortical layer, and area.

[1]  Edward S. Boyden,et al.  A history of optogenetics: the development of tools for controlling brain circuits with light , 2011, F1000 biology reports.

[2]  R. Mandel,et al.  Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Ilana B. Witten,et al.  Recombinase-Driver Rat Lines: Tools, Techniques, and Optogenetic Application to Dopamine-Mediated Reinforcement , 2011, Neuron.

[4]  Guoan Zheng,et al.  An optical neural interface : in vivo control of rodent motor cortex with integrated fiberoptic and optogenetic technology , 2016 .

[5]  J. Butler.  Optogenetics: shining a light on the brain , 2012 .

[6]  R. Mandel,et al.  Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  G. Bormans,et al.  Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. , 2009, Human gene therapy.

[8]  P. Aebischer,et al.  Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Kenneth P Vives,et al.  Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  D. Hampson,et al.  Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice. , 2013, Human gene therapy methods.

[11]  Gabriele Mittermeyer,et al.  Axonal transport of adeno-associated viral vectors is serotype-dependent , 2012, Gene Therapy.

[12]  Shu Wang,et al.  CMV enhancer/human PDGF-β promoter for neuron-specific transgene expression , 2004 .

[13]  S. Kügler,et al.  Promoters and serotypes: targeting of adeno‐associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo , 2005, Experimental physiology.

[14]  J. Gale,et al.  Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum. Laboratory investigation. , 2011, Journal of neurosurgery.

[15]  A. Toga,et al.  The Rhesus Monkey Brain in Stereotaxic Coordinates , 1999 .

[16]  Shuyun Dong,et al.  Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs , 2010, Nature Protocols.

[17]  P. Aebischer,et al.  Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles. , 2013, Human gene therapy.

[18]  Philippe Hantraye,et al.  Applications of lentiviral vectors for biology and gene therapy of neurological disorders. , 2008, Current gene therapy.

[19]  I. Bièche,et al.  Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. , 2010, Human molecular genetics.

[20]  S. Rumpel,et al.  Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain , 2013, PloS one.

[21]  Philippe Hantraye,et al.  Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia , 2009, Science Translational Medicine.

[22]  Michael B. Stadler,et al.  Encoding of conditioned fear in central amygdala inhibitory circuits , 2010, Nature.

[23]  Karl Deisseroth,et al.  Optogenetics in Neural Systems , 2011, Neuron.

[24]  Donald W. Pfaff,et al.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.

[25]  Matthew T. Kaufman,et al.  An optogenetic toolbox designed for primates , 2011, Nature Neuroscience.

[26]  D. Watanabe,et al.  Viral vector-mediated selective and reversible blockade of the pathway for visual orienting in mice , 2013, Front. Neural Circuits.

[27]  Karl Deisseroth,et al.  Optical activation of lateral amygdala pyramidal cells instructs associative fear learning , 2010, Proceedings of the National Academy of Sciences.

[28]  K. Deisseroth,et al.  Parvalbumin neurons and gamma rhythms enhance cortical circuit performance , 2009, Nature.

[29]  P. Pivirotto,et al.  Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  M. Moser,et al.  Optogenetic Dissection of Entorhinal-Hippocampal Functional Connectivity , 2013, Science.

[31]  David V Schaffer,et al.  The AAV Vector Toolkit: Poised at the Clinical Crossroads. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  R. Guillery,et al.  Functional organization of thalamocortical relays. , 1996, Journal of neurophysiology.

[33]  Hong Yu Chen,et al.  Oligodendrocyte‐specific gene expression in mouse brain: Use of a myelin‐forming cell type–specific promoter in an adeno‐associated virus , 1999, Journal of neuroscience research.

[34]  A. Hendrickson,et al.  Calcium‐binding proteins as markers for subpopulations of GABAergic neurons in monkey striate cortex , 1990, The Journal of comparative neurology.

[35]  Anatol C. Kreitzer,et al.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.

[36]  P. Reier,et al.  Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  D. Watanabe,et al.  Genetic dissection of the circuit for hand dexterity in primates , 2012, Nature.

[38]  Jacob G. Bernstein,et al.  Millisecond-Timescale Optical Control of Neural Dynamics in the Nonhuman Primate Brain , 2009, Neuron.

[39]  Wim Vanduffel,et al.  Optogenetics in primates: a shining future? , 2013, Trends in genetics : TIG.

[40]  Dae-Shik Kim,et al.  Global and local fMRI signals driven by neurons defined optogenetically by type and wiring , 2010, Nature.

[41]  J. Betley,et al.  Adeno-associated viral vectors for mapping, monitoring, and manipulating neural circuits. , 2011, Human gene therapy.

[42]  G. Breese,et al.  Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector , 1996, Brain Research.

[43]  W. Denk,et al.  Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P Osten,et al.  Viral vectors: a wide range of choices and high levels of service. , 2007, Handbook of experimental pharmacology.

[45]  J. Feldon,et al.  Transduction Profiles of Recombinant Adeno-Associated Virus Vectors Derived from Serotypes 2 and 5 in the Nigrostriatal System of Rats , 2004, Journal of Virology.

[46]  Edward M. Callaway,et al.  Short Promoters in Viral Vectors Drive Selective Expression in Mammalian Inhibitory Neurons, but do not Restrict Activity to Specific Inhibitory Cell-Types , 2009, Frontiers in neural circuits.

[47]  J. Kordower,et al.  Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  David R Williams,et al.  Intravitreal injection of AAV2 transduces macaque inner retina. , 2011, Investigative ophthalmology & visual science.

[49]  G. Orban,et al.  Visual Motion Processing Investigated Using Contrast Agent-Enhanced fMRI in Awake Behaving Monkeys , 2001, Neuron.

[50]  S. Wang,et al.  CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. , 2004, Gene therapy.

[51]  T. Yamamori,et al.  Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex , 2015, Neurosciences research.

[52]  Ren-Ke Li,et al.  Human CMV immediate‐early enhancer: a useful tool to enhance cell‐type‐specific expression from lentiviral vectors , 2008, The journal of gene medicine.

[53]  C. Gall,et al.  Differential effects of monocular deprivation on glutamic acid decarboxylase and type II calcium-calmodulin-dependent protein kinase gene expression in the adult monkey visual cortex [published erratum appears in J Neurosci 1991 May;11(5):following Table of Contents] , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[54]  T. McCown.  Adeno-Associated Virus (AAV) Vectors in the CNS. , 2005, Current gene therapy.

[55]  B. Davidson,et al.  Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors , 2000, Neuroreport.

[56]  N. Déglon,et al.  Viral vectors as tools to model and treat neurodegenerative disorders , 2005, The journal of gene medicine.

[57]  KouichiC . Nakamura,et al.  Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters , 2007, Gene Therapy.

[58]  J. Verhaagen,et al.  Viral vectors, tools for gene transfer in the nervous system , 1998, Progress in Neurobiology.

[59]  R. Samulski,et al.  Viral vectors for gene delivery to the central nervous system , 2012, Neurobiology of Disease.

[60]  K. Obata,et al.  Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors , 2009, Neuroscience.

[61]  Edilson Ervolino,et al.  Cyto-, myelo- and chemoarchitecture of the prefrontal cortex of the Cebus monkey , 2011, BMC Neuroscience.

[62]  Zeger Debyser,et al.  Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. , 2007, Human gene therapy.

[63]  F. Coun,et al.  Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9 , 2011, Gene Therapy.

[64]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[65]  R. Samulski,et al.  Integration of adeno-associated virus (AAV) and recombinant AAV vectors. , 2004, Annual review of genetics.

[66]  E. G. Jones,et al.  Localization of alpha type II calcium calmodulin-dependent protein kinase at glutamatergic but not gamma-aminobutyric acid (GABAergic) synapses in thalamus and cerebral cortex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Mehrdad Jazayeri,et al.  Saccadic eye movements evoked by optogenetic activation of primate V1 , 2012, Nature Neuroscience.

[68]  J. Malpeli,et al.  The representation of the visual field in the lateral geniculate nucleus of Macaca mulatta , 1975, The Journal of comparative neurology.

[69]  J. Uney,et al.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells) , 2009, Cell Biology and Toxicology.

[70]  M. King,et al.  Dose and Promoter Effects of Adeno-Associated Viral Vector for Green Fluorescent Protein Expression in the Rat Brain , 2002, Experimental Neurology.

[71]  V. Choi,et al.  AAV hybrid serotypes: improved vectors for gene delivery. , 2005, Current gene therapy.

[72]  Lief E. Fenno,et al.  Amygdala circuitry mediating reversible and bidirectional control of anxiety , 2011, Nature.

[73]  R. Barker,et al.  Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial , 2014, The Lancet.

[74]  Nathan C. Klapoetke,et al.  A High-Light Sensitivity Optical Neural Silencer: Development and Application to Optogenetic Control of Non-Human Primate Cortex , 2010, Front. Syst. Neurosci..

[75]  L. Arckens,et al.  Evaluation of the expression pattern of rAAV2/1, 2/5, 2/7, 2/8, and 2/9 serotypes with different promoters in the mouse visual cortex , 2015, The Journal of comparative neurology.

[76]  R. Samulski,et al.  Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.

[77]  Karl Deisseroth,et al.  Controlling the brain with light , 2010 .

[78]  B. Roth,et al.  Remote Control of Neuronal Signaling , 2011, Pharmacological Reviews.

[79]  Krystof S. Bankiewicz,et al.  ADENO-ASSOCIATED VIRUS TYPE 6 IS RETROGRADELY TRANSPORTED IN THE NON-HUMAN PRIMATE BRAIN , 2013, Gene Therapy.

[80]  Matt Wachowiak,et al.  Transgene Expression in Target-Defined Neuron Populations Mediated by Retrograde Infection with Adeno-Associated Viral Vectors , 2013, The Journal of Neuroscience.

[81]  E G Jones,et al.  Cell- and Lamina-Specific Expression and Activity-Dependent Regulation of Type II Calcium/Calmodulin-Dependent Protein Kinase Isoforms in Monkey Visual Cortex , 1998, The Journal of Neuroscience.

[82]  John F Neumaier,et al.  Grateful DREADDs: Engineered Receptors Reveal How Neural Circuits Regulate Behavior , 2012, Neuropsychopharmacology.